Novo Nordisk A/S: Danish pharma leader in diabetes and obesity drugs (Ozempic, Wegovy).
Price
39.57
24H
—
Volume 24h
$5.47K
Market Cap
$172.35B
| Venues | Issuers | Symbol | Mark | Volume 24h | Liquidity | Vol % | Contract |
|---|---|---|---|---|---|---|---|
 Binance Alpha |  | NVOon | 38.97 | $2.74K | — | 50.1% | 0x08a5…28a8 |
 Ondo Markets | | NVO | 40.17 | $2.73K | — | 49.9% | 0x2815…93e3 |
 Solana |  | XsfAzP…87S57n | 37.99 | — | $1.77K | — | XsfAzP…S57n |
News
20NVONovo Nordisk considers upgrading its US listing, FT reports
14hNVONovo Nordisk aims to keep operating margin broadly stable through 2030
×72dNVO▲Novo Nordisk says half of Wegovy U.S. sales come from cash-pay channels, while oral drugs reach 90%
×22dNVO▲Novo Nordisk is expanding into women’s and men’s health in new markets
×22d